Cargando…

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease

Peroxisome proliferator-activated receptors (PPARs) have been suggested to play crucial roles in the pathology of NAFLD with a vague understanding of the underlying mechanism. Here, we integrated large-scale literature data and clinical data to explore the potential role of the PPAR-APOA1 signaling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Changxi, Li, Hongliang, Song, Jian, Zhang, Cheng, Li, Mengting, Mao, Yushan, Liu, Aiming, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886744/ https://www.ncbi.nlm.nih.gov/pubmed/35242173 http://dx.doi.org/10.1155/2022/4709300

Ejemplares similares

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease
por: Zheng, Rongjiong, et al.
Publicado: (2018)

Immunoregulatory Effect of Koumine on Nonalcoholic Fatty Liver Disease Rats
por: Yue, Rongcai, et al.
Publicado: (2019)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway
por: Du, Tingyi, et al.
Publicado: (2022)

Association of Serum Apolipoprotein A5 Concentration with Nonalcoholic Fatty Liver Disease in Ningbo, China
por: Liu, Xiao, et al.
Publicado: (2022)

TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis
por: Zhang, Yanmei, et al.
Publicado: (2021)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway
por: Lin, Min-Jie, et al.
Publicado: (2017)

HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels
por: Chen, Changxi, et al.
Publicado: (2020)

Myeloid-specific blockade of Notch signaling ameliorates nonalcoholic fatty liver disease in mice
por: Ding, Jian, et al.
Publicado: (2023)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Predicting the 5-Year Risk of Nonalcoholic Fatty Liver Disease Using Machine Learning Models: Prospective Cohort Study
por: Huang, Guoqing, et al.
Publicado: (2023)

External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population
por: Zhang, Liuxin, et al.
Publicado: (2022)

Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
por: Zhong, Jing, et al.
Publicado: (2023)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
por: Videla, Luis A., et al.
Publicado: (2012)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

Co-exposure to multi-walled carbon nanotube and lead ions aggravates hepatotoxicity of nonalcoholic fatty liver via inhibiting AMPK/PPARγ pathway
por: Liu, Enqin, et al.
Publicado: (2020)

Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
por: Paiva, Adriene A., et al.
Publicado: (2017)

Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease
por: Sun, Xulong, et al.
Publicado: (2020)

Nutrigenetic Interaction Between Apolipoprotein C3 Polymorphism and Fat Intake in People with Nonalcoholic Fatty Liver Disease
por: Yamamoto, Reina, et al.
Publicado: (2023)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Association between apolipoprotein E gene polymorphism and nonalcoholic fatty liver disease in Southern China: A case‐control study
por: Liu, Sudong, et al.
Publicado: (2021)

Dietary Flaxseed Oil Prevents Western-Type Diet-Induced Nonalcoholic Fatty Liver Disease in Apolipoprotein-E Knockout Mice
por: Han, Hao, et al.
Publicado: (2017)

Citrus maxima and tea regulate AMPK signaling pathway to retard the progress of nonalcoholic fatty liver disease
por: Wen, Shuai, et al.
Publicado: (2022)

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis
por: Qiu, Han, et al.
Publicado: (2022)

Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease
por: Ding, Yajie, et al.
Publicado: (2023)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease
por: Huang, Yuanshe, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
por: Han, Yoon-Mi, et al.
Publicado: (2020)

Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway
por: Guo, Yi, et al.
Publicado: (2017)

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
por: Huang, Yue Ye, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ufvtnjv8v2r20lsvmn6dluhaic